Want to see LQDA full AI Analyst Report?
LQDA Stock Chart & Stats
$70.49
$0.15(0.17%)
At close: 4:00 PM EDT
$70.49
$0.15(0.17%)
Day’s Range― - ―
52-Week Range$22.05 - $93.61
Previous CloseN/A
Volume722.63K
Average Volume (3M)5.19M
Market Cap
$3.82B
Enterprise Value$7.98B
Total Cash (Recent Filing)$284.18M
Total Debt (Recent Filing)$128.94M
Price to Earnings (P/E)27.2
Beta1.44
Next Earnings
Nov 10, 2026EPS Estimate
0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.57
Shares Outstanding89,508,890
10 Day Avg. Volume6,476,743
30 Day Avg. Volume5,194,322
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)66.33
Price to Sales (P/S)18.75
P/FCF Ratio-74.16
Enterprise Value/Market Cap2.09
Enterprise Value/Revenue17.70
Enterprise Value/Gross Profit19.15
Enterprise Value/Ebitda44.89
Forecast
1Y Price Target
$53.13Price Target Upside-24.63% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)2.09
Revenue Forecast (FY)$716.99M
Bulls Say, Bears Say
Bulls Say
Commercial TractionRapid prescription growth, patient starts, and quarterly sales expansion indicate meaningful physician adoption and commercial execution. YUTREPIA’s approaching 30% share of the inhaled market provides a growing revenue base that can support continued scale and reinforce Liquidia’s position in pulmonary hypertension.
Profitability And Cash GenerationThe combination of strong quarterly earnings, adjusted EBITDA, and a rising cash balance shows operating leverage emerging alongside commercialization. This improves Liquidia’s ability to fund clinical development, support its commercial platform, and absorb planned investment without relying solely on external capital.
Pipeline ExpansionA broad clinical program gives Liquidia multiple opportunities to extend its treprostinil franchise across indications and dosing strategies. Progress on L606 and Re-Spire could address product convenience and expand future revenue sources, reducing reliance on a single approved use over time.
Bears Say
Patent Settlement And Indication LossThe settlement resolves litigation but materially reduces near-term financial flexibility through substantial cash payments and removes the PH-ILD indication from the label. That narrows YUTREPIA’s approved commercial scope and may constrain resources available for development and expansion.
Four-times-daily DosingThe current dosing frequency creates a lasting convenience and adherence disadvantage for some patients compared with less frequent regimens. Until L606 advances, this product characteristic may limit adoption in parts of the market and increase dependence on continued education and prescriber support.
Rising Operating InvestmentPlanned increases in R&D and commercial spending are strategically aimed at advancing L606, expanding indications, and supporting sales growth, but they will raise the cost base materially. If revenue growth moderates, higher expenses could pressure margins and reduce cash accumulation.
Liquidia Technologies News
LQDA FAQ
What was Liquidia Technologies Inc’s price range in the past 12 months?
Liquidia Technologies Inc lowest stock price was $22.05 and its highest was $93.61 in the past 12 months.
What is Liquidia Technologies Inc’s market cap?
Liquidia Technologies Inc’s market cap is $3.82B.
When is Liquidia Technologies Inc’s upcoming earnings report date?
Liquidia Technologies Inc’s upcoming earnings report date is Nov 10, 2026 which is in 17 days.
How were Liquidia Technologies Inc’s earnings last quarter?
Liquidia Technologies Inc released its earnings results on Aug 12, 2026. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.743 by -$0.003.
Is Liquidia Technologies Inc overvalued?
According to Wall Street analysts Liquidia Technologies Inc’s price is currently Overvalued.
Does Liquidia Technologies Inc pay dividends?
Liquidia Technologies Inc does not currently pay dividends.
What is Liquidia Technologies Inc’s EPS estimate?
Liquidia Technologies Inc’s EPS estimate is 0.92.
How many shares outstanding does Liquidia Technologies Inc have?
Liquidia Technologies Inc has 89,508,890 shares outstanding.
What happened to Liquidia Technologies Inc’s price movement after its last earnings report?
Liquidia Technologies Inc reported an EPS of $0.74 in its last earnings report, missing expectations of $0.743. Following the earnings report the stock price went down -10.517%.
Which hedge fund is a major shareholder of Liquidia Technologies Inc?
Currently, no hedge funds are holding shares in LQDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Liquidia Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.13 (-24.63% Downside)
$53.13 (-24.63% Downside)
Blogger Sentiment
Bullish
LQDA Sentiment 61%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 285.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $36.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 17.8%
Last 30 Days ▼ 17.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
93.68%
12-Months-Change
Fundamentals
Return on Equity
149.64%
Trailing 12-Months
Asset Growth
102.76%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Liquidia Technologies Inc
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
LQDA Company Deck
LQDA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum—robust quarter-over-quarter sales (+31%), substantial patient adoption (~5,000+ patients started) and improving profitability (net income ~$74.7M, adjusted EBITDA ~$96.3M) alongside a healthy cash build (~$284M). Clinical data and a progressing pipeline (10 studies, L606 Phase III enrollment) underpin future growth potential. Offsetting factors include a 4x daily dosing requirement for the current product, planned increases in R&D and SG&A (R&D expected to double in H2 2026), pending patent litigation that could create legal/royalty risk, and the need for further community penetration. On balance, the positive operational, financial, and clinical developments materially outweigh the manageable near-term risks.View all LQDA earnings summariesLQDA Stock 12 Month Forecast
Average Price Target
$53.13
▼(-24.63% Downside)
Technical Analysis
Corcept Therapeutics
―
SCYNEXIS
―
Kiniksa Pharmaceuticals
―
Nasus Pharma Ltd.
―
Clinuvel Pharmaceuticals Limited Sponsored ADR
―
Ownership Overview
29.57% Insiders
8.40% Mutual Funds
0.94% Other Institutional Investors
40.13% Public Companies and
Individual Investors